• 284 Citations
  • 10 h-Index
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 4 Similar Profiles
Venous Thromboembolism Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Anticoagulants Medicine & Life Sciences
Pulmonary Embolism Medicine & Life Sciences
Breast Neoplasms Medicine & Life Sciences
Jordan Medicine & Life Sciences
Warfarin Medicine & Life Sciences
Venous Thrombosis Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1997 2019

  • 284 Citations
  • 10 h-Index
  • 24 Article
  • 12 Review article
  • 7 Letter
  • 1 Conference contribution
1 Citation (Scopus)
Breast Neoplasms
Drug Approval
Estrogen Receptors

Intensity of Cancer Care Near the End of Life at a Tertiary Care Cancer Center in Jordan

Abdel-Razeq, H., Shamieh, O., Abu-Nasser, M., Nassar, M., Samhouri, Y., Abu-Qayas, B., Asfour, J., Jarrah, J., Abdelrahman, Z., Ameen, Z., Al-Hawamdeh, A. R., Alomari, M., Al-Tabba', A., Al-Rimawi, D. & Hui, D., Jan 1 2019, In : Journal of pain and symptom management.

Research output: Contribution to journalArticle

Terminal Care
Tertiary Care Centers
Drug Therapy
Odds Ratio
Open Access
Vitamin D
Breast Neoplasms

Towards Digital Cancer Genetic Counseling

Abujamous, L., Tbakhi, A., Odeh, M., Alsmadi, O., Kharbat, F. F. & Abdel-Razeq, H., Jan 17 2019, Proceedings - 2018 1st International Conference on Cancer Care Informatics, CCI 2018. Institute of Electrical and Electronics Engineers Inc., p. 188-194 7 p. 8618229. (Proceedings - 2018 1st International Conference on Cancer Care Informatics, CCI 2018).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Genetic Counseling
Genetic Phenomena
Breast Neoplasms

Four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (NSABP-B27) with concomitant trastuzumab as neoadjuvant therapy for high-risk, early-stage, HER2-positive breast cancer patients

Abdel-Razeq, H., Saadeh, S. S., Abu-Nasser, M., Abdulelah, H., Marie, L., Salam, M., Al-Haj Ali, B., Ibrahim, M. & Rimawi, D., Apr 11 2018, In : OncoTargets and Therapy. 11, p. 2091-2096 6 p.

Research output: Contribution to journalArticle

Neoadjuvant Therapy
Breast Neoplasms